Why Lixte Biotechnology Stock Is Soaring
Why Lixte Biotechnology Stock Is Soaring
Lixte Biotechnology Holdings, Inc. (NASDAQ:LIXT) shares are trading higher Wednesday after the company announced the publication of pre-clinical data on its lead clinical compound, LB-100.
Lixte Biotechnology Holdings, Inc.（納斯達克股票代碼：LIXT）週三股價走高，此前該公司宣佈公佈其主要臨床化合物 LB-100 的臨床前數據。
The Details:
細節：
The company announced the publication of pre-clinical data in the online journal, "Cancer Discovery", showing that its lead clinical compound, LB-100, can force cancer cells to give up their cancer-causing properties in a paper entitled "Paradoxical activation of oncogenic signaling as a cancer treatment strategy."
該公司在一篇題爲 “自相矛盾地激活致癌信號作爲癌症治療策略” 的論文中宣佈在在線期刊《癌症發現》上發佈臨床前數據，顯示其主要臨床化合物 LB-100 可以迫使癌細胞放棄其致癌特性。
Lixte said the finding opens a potentially new treatment strategy in addition to its current three clinical trials.
Lixte說，除了目前的三項臨床試驗外，這一發現還開啓了一種潛在的新治療策略。
"The effect of LB-100 on cancer cells is unique in that the only way for cancer cells to escape death is to evolve toward a less cancerous behavior. We look forward to testing this concept clinically, which is distinct from the well-characterized enhancement of checkpoint immunotherapy and chemotherapy by LB-100 currently being tested in three clinical trials," said Bas van der Baan, CEO of Lixte.
“LB-100 對癌細胞的影響是獨一無二的，因爲癌細胞逃脫死亡的唯一途徑是朝着不那麼癌的行爲進化。我們期待在臨床上測試這一概念，這與目前正在三項臨床試驗中測試的 LB-100 對檢查點免疫療法和化療的明顯增強截然不同。” Lixte首席執行官巴斯·範德巴恩說。
Lixte Biotechnology shares are moving on heavy trading volume following the announcement. According to data from Benzinga Pro, more than 21.82 million shares have already been traded in the session, compared to the stock's 100-day average of less than 38,000 shares.
宣佈後，Lixte Biotechnology的股票交易量居高不下。根據Benzinga Pro的數據，該交易日已經交易了超過2182萬股股票，而該股的100天平均交易量不到38,000股。
Related News: What's Going On With Rumble Stock?
相關新聞： Rumble 股票怎麼了？
How To Buy LIXT Stock:
如何購買 LIXT 股票：
By now you're likely curious about how to participate in the market for Lixte Biotechnology (NASDAQ:LIXT) – be it to purchase shares, or even attempt to bet against the company.
到目前爲止，你可能對如何參與Lixte Biotechnology（納斯達克股票代碼：LIXT）市場感到好奇——無論是購買股票，還是試圖對該公司下注。
Buying shares is typically done through a brokerage account. You can find a list of possible trading platforms here. Many will allow you to buy 'fractional shares,' which allows you to own portions of stock without buying an entire share. For example, some stock, like Berkshire Hathaway, or Amazon.com, can cost thousands of dollars to own just one share. However, if you only want to invest a fraction of that, brokerages will allow you to do so.
購買股票通常通過經紀賬戶完成。您可以在此處找到可能的交易平台列表。許多股票允許您購買 “部分股票”，這使您無需購買整股即可擁有部分股票。例如，某些股票，例如伯克希爾·哈撒韋公司或亞馬遜，僅擁有一股股票可能要花費數千美元。但是，如果您只想投資其中的一小部分，經紀公司將允許您這樣做。
In the the case of Lixte Biotechnology, which is trading at $3.33 as of publishing time, $100 would buy you 30.03 shares of stock.
就Lixte Biotechnology而言，截至發佈時的交易價格爲3.33美元，100美元將爲你購買30.03股股票。
If you're looking to bet against a company, the process is more complex. You'll need access to an options trading platform, or a broker who will allow you to 'go short' a share of stock by lending you the shares to sell. The process of shorting a stock can be found at this resource. Otherwise, if your broker allows you to trade options, you can either buy a put option, or sell a call option at a strike price above where shares are currently trading – either way it allows you to profit off of the share price decline.
如果你想對一家公司下注，這個過程會更加複雜。您需要訪問期權交易平台或經紀商，該經紀人將允許您 “空頭” 一股股票，將股票借給您。可以在此資源中找到做空股票的過程。否則，如果您的經紀人允許您交易期權，您可以買入看跌期權，也可以以高於當前股票交易價格的行使價賣出看漲期權——無論哪種方式，它都允許您從股價下跌中獲利。
LIXT Price Action: According to Benzinga Pro, Lixte Biotechnology shares are up 50% at $3.38 at the time of publication Wednesday.
LIXT價格走勢：根據Benzinga Pro的數據，Lixte Biotechnology的股價在週三發佈時上漲了50％，至3.38美元。
Image: Studio Iris from Pixabay
圖片：來自 Pixabay 的 Studio Iris
譯文內容由第三人軟體翻譯。